Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments
- PMID: 30810271
- PMCID: PMC6449272
- DOI: 10.1111/1759-7714.13009
Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments
Abstract
Paraneoplastic neurological autoimmunity is often associated with small-cell lung cancer (SCLC), a highly malignant neuroendocrine tumor. Paraneoplastic autoimmunity often correlates with longer survival. We describe the paraneoplastic neurological manifestations of patients with SCLC with and without SCLC-predictive autoantibodies and the correlation between autoimmunity and survival. We reviewed the records of 116 patients (51% male) from the Mayo Clinic with histopathologically confirmed SCLC for whom stored serum was available for neural autoantibody testing. Cancer was limited stage in 41%; the median age at diagnosis was 64 years. Paraneoplastic neurological manifestations were recorded in 61% (decreasing frequency: peripheral neuropathy, dysautonomia, cognitive decline, cerebellar ataxia, neuromuscular junction disorder, seizures, cranial neuropathy, movement disorder, brainstem disorder, or myelopathy). Neural autoantibodies, some with pathogenic potential, were detected in the sera of SCLC patients with and without neurological autoimmunity. The most frequent among patients with neurological manifestations were: anti-neuronal nuclear antibody-type 1, voltage-gated calcium channel (VGCC)-N-type, VGCC-P/Q-type, glutamic acid decarboxylase 65 (GAD65), SOX1, and muscle acetylcholine receptor (AChR); while the most common in patients without neurological manifestations were: GAD65, muscle-AChR, and VGCC-P/Q-type. Neither cancer stage at diagnosis nor survival correlated with neurological manifestations or autoantibody-positivity, except for shorter survival in patients with myelopathy. The only predictor of longer survival was limited-stage disease at diagnosis.
Keywords: Anti-Hu antibody; CRMP5 antibody; GABAB receptor antibody; cancer biomarker; paraneoplastic syndrome.
© 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Figures















References
-
- Zekeridou A, Griesmann GE, Lennon VA. Mutated cancer autoantigen implicated cause of paraneoplastic myasthenia gravis. Muscle Nerve 2018; 58: 600–4. - PubMed
-
- Maddison P, Gozzard P, Grainge MJ, Lang B. Long‐term survival in paraneoplastic Lambert‐Eaton myasthenic syndrome. Neurology 2017; 88: 1334–9. - PubMed
-
- Chen DS, Mellman I. Oncology meets immunology: The cancer‐immunity cycle. Immunity 2013; 39: 1–10. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical